Sparks - Basilea Pharmaceutica

Basilea has announced a further $5.4m non-dilutive award from BARDA to support the continued development of its Phase III-ready oral antibiotic, ceftibuten-ledaborbactam (CTB-LEDA), for complicated urinary tract infections (cUTIs). This represents the fourth funding tranche under the novated agreement and increases total funding committed to Basilea to $30.8m, following awards of $6m in September 2025, $6m in February 2026 and $13.3m in May 2026. The agreement provides Basilea with access to up to $159m, leaving c $128m contingent on the achievement of predefined milestones. The $172m gross contract value cited in the release includes around $14m attributable to the pre-novation period. Phase III initiation is planned for Q1 2027, with top-line data expected around early 2029. Management has previously indicated that BARDA funding is expected to fully offset late-stage development costs, materially lowering Basilea’s cash burden and execution risk.

CTB-LEDA is an oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination targeting cUTIs caused by multidrug-resistant Enterobacterales. Its potential positioning has become more nuanced following the June 2026 FDA approval of GSK/Spero’s Utebzi (tebipenem HBr), the first and only oral carbapenem approved in the US for adults with cUTIs who have limited or no alternative oral treatment options. We expect CTB-LEDA could occupy a differentiated, carbapenem-sparing niche, particularly as targeted oral or step-down therapy. CTB-LEDA holds FDA Qualified Infectious Disease Product and Fast Track designations.